Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521321 · ClinicalTrials.gov registry record · NA
Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 443
- Enrollment target
NCT05521321: Completed NA study, sponsored by Stanford University.
NCT05521321 is a NA study that has completed, run by Stanford University. The registered enrollment target is 443 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05521321, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 443 participants
- Enrollment target
Study Summary
The Stanford Tobacco Prevention Toolkit is a free, online Toolkit that consists of a curriculum, educational resources, and a resource directory to be used by educators, parents, juvenile justice workers, and healthcare providers to increase knowledge and awareness of cannabis and reduce use among youth. The aim of this study is to investigate the extent to which the curriculum changes students' intentions to use and actual use of cannabis.
Primary Outcome
Investigator-originated survey measures (questions) assess lifetime cannabis use. This outcome measure assesses cannabis use.
Interventions
- BEHAVIORAL Stanford Cannabis Awareness and Prevention curriculum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2025-05-16 |
| Phase | NA |
What the finished NCT05521321 record still lists
NCT05521321 is an interventional study that assigns participants to a tested intervention. The registered 443 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which Stanford Cannabis Awareness and Prevention curriculum is the first listed.
NCT05521321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05521321 about?
NCT05521321 is a clinical study titled "Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit". The Stanford Tobacco Prevention Toolkit is a free, online Toolkit that consists of a curriculum, educational resources, and a resource directory to be used by educators, parents, juvenile justice workers, and healthcare providers to increase knowledge and awareness of cannabis and reduce use among y...
What is the current status of trial NCT05521321?
This trial is currently completed. It is a NA study. The enrollment target is 443 participants. The study started on 2022-10-01. Estimated completion is 2025-05-16.
What interventions are being tested in trial NCT05521321?
The interventions under investigation include: Stanford Cannabis Awareness and Prevention curriculum (BEHAVIORAL).
Who is sponsoring clinical trial NCT05521321?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05521321's enrollment target sits among peer trials
443 233rd of 2000 higher than 1,768 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06780670 · 443 participants · Phase 2
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI